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Implementing non-invasive markers for liver ﬁbrosis in clinical practiceTo the Editor:
We read with interest the article by Leroy et al.
regarding a prospective, independent validation of six
non-invasive markers for liver ﬁbrosis in chronic hepati-
tis C [1]. The overall performance of the markers tested,
which included Fibrotest, Fibrometer, Hepascore, MP3,
Forns’ index and APRI, was very similar to those orig-
inally reported, the area under the ROC curve (AUR-
OC) ranging between 0.78 and 0.86 for diagnosis of
signiﬁcant ﬁbrosis (PF2 by METAVIR). The authors
tested the statistical independence of the non-invasive
scores in order to propose a logical algorithm to be used
in clinical practice and they found that some combina-
tions of non-invasive markers gave a better performance
than the single scores. Indeed, a combination of APRI
and Fibrotest allows to predict presence of signiﬁcant
ﬁbrosis with more than 90% accuracy. In their article,
Leroy and colleagues also referred to the sequential
algorithm that we had previously proposed to diagnose
liver ﬁbrosis in chronic hepatitis C [2]. In our algorithm,
APRI is used 100% as ﬁrst-line test, followed by Fibro-Table 1
Performance of two algorithms combining non-invasive markers for liver ﬁbr
patients
APRI
Patients in whom APRI was performed (%)
Fibrotest
Patients in whom Fibrotest was performeda (%)
Patients in whom
Liver biopsies was avoided (%)
Sensitivity (%)
Speciﬁcity (%)
PPV (%)
NPV (%)
Accuracy (%)
AUROC (95% CI)
+ LR
 LR
APRI, AST-to-platelet-ratio; PPV, positive predictive value; NPV, negative
interval.
a Sebastiani’s algorithm: cutoﬀ = 0.49 for signiﬁcant ﬁbrosis; Leroy’s algo
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application of this algorithm has resulted in a 50%
reduction of liver biopsies to diagnose F2 ﬁbrosis with
a diagnostic accuracy of 94%.
We sought to compare the performance of Leroy’s
algorithm and our algorithm for the diagnosis of signif-
icant ﬁbrosis in chronic hepatitis C. We investigated a
consecutive series of 188 monoinfected HCV patients
(mean age 48.6 ± 12.4, 51.6% males) who underwent a
percutaneous liver biopsy. For all patients APRI and
Fibrotest were calculated using fasting serum samples
obtained on the same day of liver biopsy. Patients with
comorbidities were excluded. METAVIR staging was:
F0–F1 = 30.5%, F2 = 45.5%, F3 = 12.5%, F4 = 11.5%.
The performance of the non-invasive methods was mea-
sured as sensitivity, speciﬁcity, positive predictive value
(PPV), negative predictive value (NPV), accuracy and
AUROC. The mean length of liver specimens was
17 ± 3 mm. The AUROCs for signiﬁcant ﬁbrosis were
0.75 and 0.79 for APRI and Fibrotest, respectively.
Table 1 shows the performance and the main featuresosis to diagnose signiﬁcant ﬁbrosis (PF2 by METAVIR) in 188 HCV
Sebastiani’s algorithm Leroy’s algorithm
100 100
60 100
54 19
100 91.2
69.3 97.3
83.1 98.1
100 87.9
87.8 93.6
0.89 (0.72–0.97) 0.94 (0.86–0.99)
3.2 3.0
0 0.09
predictive value; AUROC, area under the ROC curve; CI, conﬁdenc
rithm: cutoﬀ = 0.59 for signiﬁcant ﬁbrosis, 0.22 for no-mild ﬁbrosis.
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algorithms employed APRI 100% at baseline. The main
diﬀerence between the two algorithms was that Fibrotest
is again required for all cases according to Leroy’s algo-
rithm, while our algorithm uses Fibrotest only in 60% of
cases. Our algorithm presents with 100% NPV for the
exclusion of signiﬁcant ﬁbrosis while Leroy’s algorithm
showed 98% PPV for the prediction of signiﬁcant ﬁbro-
sis. Though the overall accuracy of both algorithms was
excellent, with a slightly better performance of Leroy’s,
the application of our algorithm resulted in a much
greater reduction of liver biopsies (54% vs. 19%,
p < 0.0001).
Reducing the need for liver biopsies and Fibrotest im-
plies a clear advantage in terms of risks, costs and better
patient-compliance.
Leroy’s study conﬁrms that most non-invasive mark-
ers do not overcome 75–85% accuracy in patients with
chronic hepatitis C. Non-invasive markers, should be
used sequentially while liver biopsy should be limited
to the subset of patients with inaccurate response to
non-invasive markers. Liver biopsy and non-invasive
markers should be considered as agonists and not as
antagonists towards the goal of correctly classifyingthe stage of liver ﬁbrosis in patients with chronic hepa-
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